Dr. Laura Cohen presenting the #TEAMHF echo data after rapid #GDMTworks clinic titration

Average 6% LVEF rise
>60% with 🔼LVEF from below to above 35%
50% 🔽in 3-4+ MR

These results emphasize the value of GDMT programs!

Mass General Heart HFAPresident

Fun times at #HeartFailure2024

Really grateful to the European Society of Cardiology #HFA organizing committee, sponsors, collaborators, & friends for the tremendous opportunities and memories.

Till we meet again..

#HeartFailure2024 #JACCHF LBCT SimPub: REALIZE-K is the first trial to test whether SZC can enable rapid & safe MRA optimization & long-term continuation in patients w/ #HFrEF & prevalent/high risk of hyperkalemia. bit.ly/3Kh4ijj

Mikhail Kosiborod Mark Petrie

Anti-obesity medications seem to be anti-heart failure drugs. Kudos Mikhail Kosiborod & team. See the video for details and the paper published JACC Journals. The paper was presented today in Lisbon European Society of Cardiology HF meetings. youtube.com/watch?v=kvqRrh… jacc.org/doi/10.1016/j.…

The third presentation is by Greg Lewis focusing on the exercise response in #SEQUOIA #HCM
#HeartFailure2024 #CardioTwitter

#HeartFailure 2024 #JACC LBCT SimPub: In the STEP-HFpEF trial, #semaglutide 2.4 mg once weekly, compared to placebo, reduced the heart failure biomarker #NTproBNP in patients with #obesity -related #HFpEF . bit.ly/4afmmof

#HeartFailure Mark Petrie Mikhail Kosiborod

🔥 of the press in the European Heart Journal: Semaglutide and Diuretic use in obesity-related HFpEF. Large effects of semaglutide on reducing loop diuretic use and dose in the STEP-HFPEF Program
Andrew J Sauer MD
Ankeet S. Bhatt, MD, MBA
Sanjiv J. Shah, MD
Kavita Sharma
Muthu Vaduganathan
academic.oup.com/eurheartj/adva…

Repost number 3 by my colleague Dr. Greg Lewis focused on exercise response in #SEQUOIA .

The #SEQUOIA #HCM trial results are here - Placebo-controlled trial of #aficamten in #obstructive #HCM

3 presentations in 3 threads - follow along

This is the first presentation by Martin Maron, MD sharing the primary results
Follow along #CardioTwitter #HeartFailure2024

There's a ripple of applause as Martin Maron, MD presents the SEQUOIA-HCM results at the #HeartFailure2024 late breaking trials session where Aficamten meets significance in primary and all ten secondary outcomes.

🔥Out now in #JCF ! This brief report shows that in the ongoing FINEARTS-HF trial, incorporating UACR reclassified kidney risk in 1/3 trial pts and US adults with HF, emphasizing the importance of albuminuria as part of comprehensive risk assessment.

🔗bit.ly/3UTfys8

1st trial on the effect of IV #iron in #HF pEF #FAIRHFPEF :

📍IV #iron ⬆️ exercise capacity using #6MWT , predominantly in elderly
📍effective regardless of #hemoglobin or etiology of #HF
📍no improvement in QOL and PGA
📍safe to use

#HeartFailure2024

Obese Cardiomyopathy by Javed Butler #HeartFailure #HeartFailure 2024

Timing of Cardio-Kidney Protection With SGLT2 Inhibitor varies in trials

Herat failure benefits occur early
MACE events evident early
Cardiovascular deaths & kidney outcome benefits much later

ahajournals.org/doi/10.1161/CI…

Brendon Neuen Muthu Vaduganathan et al

ICYMI: Dr. Mikhail Kosiborod shares 🔑 insights from his #JACC LBCT paper, exploring #semaglutide 's impact on the #heartfailure biomarker, #NTproBNP , in patients with #obesity -related #HFpEF . Don't miss the video 👇

📄: bit.ly/4afmmof

#HeartFailure2024 Harlan Krumholz

Findings suggest disease-modifying effects of semaglutide on the pathobiology of obesity-related HFpEF

How #Semaglutide affect #NTproBNP in #obesity related #HF pEF ❓insight from #STEPHFPEF

📍 #semaglutide ⬇️ #NTproBNP in obesity related #HF pEF
📍px with ⬆️baseline #NTproBNP has larger ⬇️ of #HF symptoms & physical limitation compare to ⬇️baseline

#HeartFailure2024

Epidemiology, outcomes and classifications of CS

📍CS comprises 3-5% of AHF cases.
📍AMI was main cause, but recent data shifted landscape.
📍CS is the most severe form with high mortality.
📍In-hospital mortality: 30-40%, half within 24h.
📍30% day-mortality: 45-50% in…

New findings from #DANISH trial in non-ischaemic #HFrEF patients

📍NYHA class III/IV associated with higher all-cause and CV mortality.

📍ICD implantation didn't reduce mortality rates regardless of #NYHA class. No modification of #ICD benefits by NYHA class…

Lisbon tourism with Mikhail Kosiborod